Compare Supplements

Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.

Any time

Once-weekly extended-release injection (Bydureon)

Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.

Any time

Once-weekly subcutaneous injection (investigational; China-approved as Xinermei)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease — exenatide is renally cleared

• Sulfonylureas and insulin
• Oral medications (general)
• Warfarin

• Pregnancy and breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN2 (class-level precaution for GLP-1-based agents)
• History of pancreatitis (use with caution / avoid)

• Insulin and sulfonylureas
• Oral medications generally